Tags

Type your tag names separated by a space and hit enter

Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel.
Contraception. 1983 Jun; 27(6):577-90.C

Abstract

The changes in plasma hormone levels were evaluated in matched healthy female volunteers investigated before and after 6 months' use of three new oral contraceptives (OCs): TrigynonR (n = 13), a triphasic OC containing low doses of ethinylestradiol (EE) + levonorgestrel (LNg); MarvelonR (n = 14), a monophasic OC containing low doses of EE + desogestrel (DOG, a new progestogen derived from LNg); and OvidolR (n = 10), a sequential OC containing higher doses (50 micrograms) of EE + DOG. Serum levels of FSH, LH, estradiol and progesterone were decreased in all cases to levels incompatible with ovulation. Prolactin concentrations were unchanged. Sex hormone binding globulin (SHBG) and Transcortin (CBG) levels were significantly increased by all three OCs (Ovidol greater than Marvelon greater than Trigynon); free testosterone levels decreased significantly while free cortisol concentrations remained unchanged. Collectively, these data indicate that (a) all three OCs are effective ovulation inhibitors, (b) Ovidol and Marvelon have greater estrogenic effects than Trigynon, (c) LNg is more effective than DOG in reducing the EE-induced increase in SHBG levels, and (d) free testosterone levels are equally well suppressed by all three Ocs.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

6225622

Citation

Gaspard, U J., et al. "Plasma Hormone Levels in Women Receiving New Oral Contraceptives Containing Ethinyl Estradiol Plus Levonorgestrel or Desogestrel." Contraception, vol. 27, no. 6, 1983, pp. 577-90.
Gaspard UJ, Romus MA, Gillain D, et al. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception. 1983;27(6):577-90.
Gaspard, U. J., Romus, M. A., Gillain, D., Duvivier, J., Demey-Ponsart, E., & Franchimont, P. (1983). Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception, 27(6), 577-90.
Gaspard UJ, et al. Plasma Hormone Levels in Women Receiving New Oral Contraceptives Containing Ethinyl Estradiol Plus Levonorgestrel or Desogestrel. Contraception. 1983;27(6):577-90. PubMed PMID: 6225622.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. AU - Gaspard,U J, AU - Romus,M A, AU - Gillain,D, AU - Duvivier,J, AU - Demey-Ponsart,E, AU - Franchimont,P, PY - 1983/6/1/pubmed PY - 1983/6/1/medline PY - 1983/6/1/entrez KW - Age Factors KW - Androgens KW - Biology KW - Comparative Studies KW - Contraception KW - Contraceptive Agents KW - Contraceptive Agents, Estrogen KW - Contraceptive Agents, Female KW - Contraceptive Agents, Progestin KW - Contraceptive Effectiveness KW - Contraceptive Methods--side effects KW - Endocrine System KW - Estradiol--analysis KW - Estrogens KW - Ethinyl Estradiol KW - Family Planning KW - Follicle Stimulating Hormone--analysis KW - Gonadotropins KW - Gonadotropins, Pituitary KW - Hormones KW - Levonorgestrel KW - Luteinizing Hormone--analysis KW - Oral Contraceptives--side effects KW - Physiology KW - Pituitary Hormones KW - Pregnancy Rate KW - Progestational Hormones KW - Progesterone--analysis KW - Prolactin--analysis KW - Reproductive Control Agents KW - Research Methodology KW - Studies KW - Testosterone--analysis KW - Use-effectiveness SP - 577 EP - 90 JF - Contraception JO - Contraception VL - 27 IS - 6 N2 - The changes in plasma hormone levels were evaluated in matched healthy female volunteers investigated before and after 6 months' use of three new oral contraceptives (OCs): TrigynonR (n = 13), a triphasic OC containing low doses of ethinylestradiol (EE) + levonorgestrel (LNg); MarvelonR (n = 14), a monophasic OC containing low doses of EE + desogestrel (DOG, a new progestogen derived from LNg); and OvidolR (n = 10), a sequential OC containing higher doses (50 micrograms) of EE + DOG. Serum levels of FSH, LH, estradiol and progesterone were decreased in all cases to levels incompatible with ovulation. Prolactin concentrations were unchanged. Sex hormone binding globulin (SHBG) and Transcortin (CBG) levels were significantly increased by all three OCs (Ovidol greater than Marvelon greater than Trigynon); free testosterone levels decreased significantly while free cortisol concentrations remained unchanged. Collectively, these data indicate that (a) all three OCs are effective ovulation inhibitors, (b) Ovidol and Marvelon have greater estrogenic effects than Trigynon, (c) LNg is more effective than DOG in reducing the EE-induced increase in SHBG levels, and (d) free testosterone levels are equally well suppressed by all three Ocs. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/6225622/Plasma_hormone_levels_in_women_receiving_new_oral_contraceptives_containing_ethinyl_estradiol_plus_levonorgestrel_or_desogestrel_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0010-7824(83)90023-9 DB - PRIME DP - Unbound Medicine ER -